Burning Rock Biotech Limited (BNR)
$10.78
$1.63
(17.81%)
As on 03-Sep-2026 16:00EDT
Market cap
$107 Mln
Revenue (TTM)
$513 Mln
P/E Ratio
--
P/B Ratio
1.4
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.1 %
-
ROCE
-- %
-
Industry P/E
33.81
-
EV/EBITDA
-0.2
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-55.7
-
Face value
--
-
Shares outstanding
8,813,858
7 Years Aggregate
CFO
CN¥-1,774.54 Mln
EBITDA
CN¥-3,071.35 Mln
Net Profit
CN¥-3,272.43 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Burning Rock Biotech (BNR)
| -46.5 | 21.1 | 11.8 | 37.5 | 98.9 | -11.4 | -- |
|
BSE Sensex*
| -9.5 | -2.5 | 3.1 | -4.9 | 5.4 | 5.7 | 10.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
|---|---|---|---|---|---|
|
Burning Rock Biotech (BNR)
| 198.5 | 614.2 | -58.7 | -76.4 | -58.7 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Burning Rock Biotech (BNR)
|
10.8 | 107.5 | 512.7 | -59.1 | -10.1 | -11.1 | -- | 1.4 |
| 0.3 | 15.9 | 682.6 | -37.4 | -- | 115.6 | -- | 3.3 | |
| 4.5 | 22.8 | 460.5 | -92.8 | -69.6 | 4.2 | -- | 3.0 |
Shareholding Pattern
View DetailsAbout Burning Rock Biotech (BNR)
Burning Rock Biotech Limited develops and sells cancer therapy selection tests in the People's Republic of China and the United States. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and... Development Services. The company offers next-generation sequencing (NGS)-based tissue, liquid biopsy cancer therapy selection, and prognosis prediction tests for various cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its key products include OncoScreen Focus, a multi-gene tumor mutation co-detection test kit for non-small cell lung cancer (NSCLC) patients; OncoScreen Plus, a pan-cancer test for tissue samples; OncoCompass Plus, a corresponding test for liquid biopsy samples; OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC; and ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal and related cancers. The company also provides CanCatch, a pre-operative ctDNA detection and post-operative minimal residual disease calling for relapsed patients; OncoMaster, an automatic NGS data analysis and report interpretation machine; as well as Magnis BR-customized version of its key products. In addition, it engages in the facilitation of laboratory equipment sales and sales of reagent kits. The company has a development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, IMPACT Therapeutics, Boehringer Ingelheim, and Merck KGaA. Burning Rock Biotech Limited was founded in 2014 and is headquartered in Guangzhou, the People's Republic of China. Read more
-
Founder, Chairman & CEO
Mr. Yusheng Han
-
Founder, Chairman & CEO
Mr. Yusheng Han
-
Headquarters
Guangzhou
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Burning Rock Biotech (BNR)
What is the current share price of Burning Rock Biotech Limited (BNR) Today?
The share price of Burning Rock Biotech Limited (BNR) is $10.78 (NASDAQ) as of 03-Sep-2026 16:00 EDT. Burning Rock Biotech Limited (BNR) has given a return of 98.9% in the last 3 years.
What is the current PB & PE ratio of Burning Rock Biotech Limited (BNR)?
Since, TTM earnings of Burning Rock Biotech Limited (BNR) is negative, P/E ratio is not available.
The P/B ratio of Burning Rock Biotech Limited (BNR) is 1.37 times as on 28-Aug-2026, a 61 discount to its peers’ median range of 3.54 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-0.38 |
0.04 |
2024 |
-2.10 |
1.25 |
2023 |
0.00 |
0.00 |
2022 |
0.00 |
0.00 |
2021 |
-0.01 |
0.01 |
What is the 52 Week High and Low of Burning Rock Biotech Limited (BNR)?
The 52-week high and low of Burning Rock Biotech Limited (BNR) are Rs 41.72 and Rs 6.79 as of 04-Sep-2026.
What is the market cap of Burning Rock Biotech Limited (BNR)?
Burning Rock Biotech Limited (BNR) has a market capitalisation of $ 107 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Burning Rock Biotech Limited (BNR)?
Before investing in Burning Rock Biotech Limited (BNR), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.